<SEC-DOCUMENT>0001070081-23-000056.txt : 20231019
<SEC-HEADER>0001070081-23-000056.hdr.sgml : 20231019
<ACCEPTANCE-DATETIME>20231019080358
ACCESSION NUMBER:		0001070081-23-000056
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20231018
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231019
DATE AS OF CHANGE:		20231019

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		231333375

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tmb-20231018x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.4.0.13 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 10/19/2023 12:43:45 AM -->
      <!-- iXBRL Library version: 1.0.8630.22539 -->
      <!-- iXBRL Service Job ID: c38a723d-11a6-4196-84d6-e5002c40c55b -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptct="http://www.ptcbio.com/20231018" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:EntityCentralIndexKey" id="Tc_96dA-KGkLkmcqdKvZIIbVg_2_1">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:AmendmentFlag" id="Tc_vwTcQjKGxUanAV1kMfGZaQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="tmb-20231018.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-18</xbrli:startDate><xbrli:endDate>2023-10-18</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3fc39a1a_887a_483a_8c79_81c09bc11603"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:DocumentType" id="Narr_EZoJRqzjuk2w0yOB76aKYw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;white-space:pre-wrap;">Date of Report (Date of earliest event reported):  </span><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_wEVWRWI2kESkF5MiWlGf6Q"><b style="font-size:9pt;font-weight:bold;">October 18, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:EntityRegistrantName" id="Narr_okMUaYASh0W7HY9LocRYrg"><b style="font-weight:bold;">PTC THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55447ebd_8ac3_48f2_9214_a2803b87ebd3"></a><a id="Tc_e1rP_R4b5kOd-opoImU_gw_2_0"></a><a id="Tc_akZupEPK90-w1lXHPDeczA_2_2"></a><a id="Tc_5amgcuaSWEWMx4b5a1zEYA_2_4"></a><a id="Tc_MU0cvWY_GE223a-Z20kSNA_3_0"></a><a id="Tc_l7cgkp3f1U-dXst_nC8uPQ_3_2"></a><a id="Tc_MA96TV5lrEGY-f5niLh7_g_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_ucEgepRznEqlUtNZhqNvIA_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:EntityFileNumber" id="Tc_qLRBi6oEU0CAREPcFvL3Fw_1_2"><b style="font-size:9pt;font-weight:bold;">001-35969</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:EntityTaxIdentificationNumber" id="Tc_f7U3dMiFHkCtrj4ah5oikg_1_4"><b style="font-size:9pt;font-weight:bold;">04-3416587</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or Other Jurisdiction</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer</p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">of Incorporation)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_c0dd52bc_18a5_4ddb_b41a_c697e874a0ff"></a><a id="Tc_pnsKlOC08EeSJk6XBX-dIg_2_0"></a><a id="Tc_5ieqJhmbRE6cLhnBhamU0Q_3_0"></a><a id="Tc_63RZ8iQjEkyJsk0gJdXglg_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:EntityAddressAddressLine1" id="Tc_gRSowEp3lkOb1W0sy0z4hA_1_0"><b style="font-size:9pt;font-weight:bold;">100 Corporate Court</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:EntityAddressCityOrTown" id="Narr_vqWhyyVuTkesEdhmYvJ5qw"><b style="font-size:9pt;font-weight:bold;">South Plainfield</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:EntityAddressStateOrProvince" id="Narr_wj9jbgWEJUypsU4QmeR4kA"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:EntityAddressPostalZipCode" id="Tc_wXAR1LIHNkSUXKMLmP98Rw_2_2"><b style="font-size:9pt;font-weight:bold;">07080</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:CityAreaCode" id="Narr_wxt7V5DOOUmphhNYfC7hlw"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:LocalPhoneNumber" id="Narr_wBOEK6X62k-6XBdnSHrS5A"><b style="font-size:9pt;font-weight:bold;">222-7000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_f9RtLTDHjk-7RF1EA4rpZg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_tzzOEoQYSkWPEpJQsbG3Ng"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_t5dTlvCuCEKAl17kaHJ1Ng"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_PdndMp6y3UyYRgNvVS-HcA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_78f9e492_9551_4dcc_bd52_e93e8cab4c26"></a><a id="Tc_YAc9jQ8jO0itd00QEodVxA_1_0"></a><a id="Tc_Bc8-vMLhuUWZCaEG8xVLFg_1_2"></a><a id="Tc__fEai4MBYkqi7_ToR117JQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:Security12bTitle" id="Tc_13I3HE1VyUuj29pEBv_DlA_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" name="dei:TradingSymbol" id="Tc__NtkylRUVU2khUPonaiqow_2_2"><span style="font-size:9pt;">PTCT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_l3woA2JwCE61GH4m-NoWeA_2_4"><span style="font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_YAUnj_4JkkiFYDEpZ3Kq1A"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-bottom:6pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_b4edbce2_2632_49cf_b953_6efb92eebea5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1.01. </b><b style="color:#211d1e;font-weight:bold;">Entry into a Material Definitive Agreement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">On October 18, 2023, PTC Therapeutics, Inc. (the &#8220;Company&#8221;), Royalty Pharma Investments 2019 ICAV (&#8220;RPI&#8221;), and, for the limited purposes set forth in the agreement, Royalty Pharma plc, entered into an Amended and Restated Royalty Purchase Agreement (the &#8220;A&amp;R Royalty Purchase Agreement&#8221;), which amends and restates in its entirety that certain Royalty Purchase Agreement dated as of July 17, 2020 (the &#8220;Original Royalty Purchase Agreement&#8221;).  Pursuant to the A&amp;R Royalty Purchase Agreement, the Company has sold or agreed to sell to RPI certain portions of the Company&#8217;s remaining retained right, title and interest in and to the Company&#8217;s right to receive sales-based royalty payments (the &#8220;Royalty&#8221;) on worldwide net sales of Roche&#8217;s Evrysdi&#174; (risdiplam) product and any other product (the &#8220;Products&#8221;) developed pursuant to the License and Collaboration Agreement (the &#8220;License Agreement&#8221;), dated as of November 23, 2011, by and among the Company, F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc. (together with F. Hoffman-La Roche Ltd, &#8220;Roche&#8221;), and, for the limited purposes set forth therein, the Spinal Muscular Atrophy Foundation (the &#8220;SMA Foundation&#8221;) under the SMA program, which is a collaboration among the Company, Roche and the SMA Foundation (all such retained Royalty rights of the Company, the &#8220;Retained Royalty Rights,&#8221; and all such Royalty rights that are sold to RPI pursuant to the A&amp;R Royalty Purchase Agreement, the &#8220;Assigned Royalty Rights&#8221;).  As of the initial closing, RPI has agreed to pay the Company $1.0 billion in cash consideration for 38.0447% of the Company&#8217;s Retained Royalty Rights (which is in addition to the 42.9330% assigned to RPI in connection with the Original Royalty Purchase Agreement, for a total of 80.9777% of the total Royalty) until such time as RPI has received payments in respect of the Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 66.6667% of the total Royalty.  In addition, the Company may sell to RPI the remainder of the Company&#8217;s Retained Royalty Rights in exchange for an aggregate of $500.0 million in additional cash consideration after the closing of the A&amp;R Royalty Purchase Agreement, less royalties received in respect of the Retained Royalty Rights put to RPI, which will be payable by RPI pursuant to five put options held by the Company that are exercisable at the Company&#8217;s option between January 1, 2024 and December 31, 2025.  If the Company exercises two or fewer of the put options, RPI may exercise a call option during the period from and after January 1, 2026 until and including March 31, 2026 for up to 50% of the remainder of the Company&#8217;s Retained Royalty Rights less amounts exercised by the Company via their put options at a purchase price that is proportional to the purchase price of the Company&#8217;s unexercised put options. RPI&#8217;s exercise of the call option would result in RPI owning 90.4888% of the total Royalty until such time as RPI has received payments in respect of the Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 83.3333% of the total Royalty. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">Under the A&amp;R Royalty Purchase Agreement, and in connection with its sale of the Assigned Royalty Rights, the Company has agreed to specified negative and affirmative covenants with respect to the exercise of its rights under the License Agreement, including the Company&#8217;s right to amend, modify, assign or terminate the License Agreement.  The Company has agreed not to exercise its rights under the License Agreement in any manner that would be expected to adversely impact the Royalty or the Products.  The Company must also enforce the terms of the License Agreement as RPI reasonably requests in the event of a breach of the License Agreement by Roche or the SMA Foundation.  Subject to the satisfaction of certain conditions, the Company has also agreed to consult with RPI or act at RPI&#8217;s direction with respect to the Company&#8217;s exercise of its rights to the enforce, defend, prosecute and maintain intellectual property rights under the License Agreement.  Subject to certain customary exceptions, the Company has agreed not to grant a security interest in its interest in the License Agreement, the Products or the patent rights that cover the Products.  The A&amp;R Royalty Purchase Agreement also contains representations and warranties, covenants and other provisions, including information rights and confidentiality obligations, customary for transactions of this nature.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">The A&amp;R Royalty Purchase Agreement will terminate 60 days following the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the License Agreement.  Upon termination of the License Agreement by Roche for convenience or by the Company for Roche&#8217;s material breach or patent challenge, (1) the Company will have the first right to continue to commercialize the Products pursuant to the rights provided to the Company upon such termination of the License Agreement and (2) if the Company does not elect to continue to commercialize the Products, RPI will have the right to direct the Company to continue to commercialize the Products pursuant to the rights provided to the Company upon such termination of the License Agreement, including by negotiating a license or sublicense with one or more third parties to commercialize a Product that has obtained regulatory approval.</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The foregoing description of the A&amp;R Royalty Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the A&amp;R Royalty Purchase Agreement, which will be filed as an exhibit to the Company&#8217;s annual report on Form 10-K for the fiscal year ending December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_9b446334_af59_45da_abd2_d32725a40719"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 7.01. Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On October 19, 2023, the Company issued a press release in which it announced the closing of the A&amp;R Royalty Purchase Agreement and its intention to pay off all obligations under the Credit Agreement (as defined below). A copy of the press release is attached to this Current Report on Form 8-K (this &#8220;Report&#8221;) as Exhibit 99.1 and is incorporated by reference into this Item 7.01.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The information set forth in or incorporated by reference into this Item 7.01, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_31e31ab9_c5c4_4b77_bd3f_4465e28b6b3c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 8.01. </b><b style="color:#211d1e;font-weight:bold;">Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The Company has provided a Notice of Loan Prepayment to Wilmington Trust, National Association (&#8220;Wilmington Trust&#8221;), notifying Wilmington Trust, in its capacity as administrative agent, of the Company&#8217;s intention to pay off all obligations, including any prepayment fees or expenses, under the Credit Agreement, dated October 27, 2022, by and among the Company, as the borrower, each subsidiary of the Company from time to time party thereto, as guarantors, the lenders from time to time party thereto and Wilmington Trust, as administrative agent (the &quot;Credit Agreement&quot;), and to terminate the Credit Agreement on October 19, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_48095604_0281_4f13_826d_d5402f0cd453"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.01.&#160;Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20231018xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated October 19, 2023 issued by PTC Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cautionary Statement Concerning Forward Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Report contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this Report, other than those of historical fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC; advancement of the Company&#39;s joint collaboration program in SMA, including the commercialization of any products therein or royalty or milestone payments; the Company&#39;s strategy, future operations, future financial position, future revenues and projected costs; the Company&#8217;s expected use of proceeds from the A&amp;R Royalty Purchase Agreement, including the Company&#8217;s intention to pay off all obligations under and to terminate the Credit Agreement; potential royalties and potential regulatory and sales milestone payments; and the objectives of management.&#160; Other forward-looking statements may be identified by the words &#8220;guidance&#8221;, &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; and similar expressions.&#160; The Company&#8217;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the enrollment, conduct, and results of studies under the SMA program and events during, or as a result of, the studies that could delay or prevent further development under the SMA program, including any potential regulatory submissions and potential commercialization with regard to Evrysdi; the eligible patient base and commercial potential of Evrysdi or any of the Company&#8217;s other product candidates; and the factors discussed in the &#8220;Risk Factors&#8221; section of the Company&#8217;s most recent Quarterly Report on Form&#160;10-Q and Annual Report on Form&#160;<span style="white-space:pre-wrap;">10-K as well as any updates to these risk factors filed from time to time in the Company&#8217;s other filings with the Securities and Exchange Commission.  You are urged to carefully consider all such factors.&#160;As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and </span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">commercialization of new products. There are no guarantees that any product candidate or product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Evrysdi.  The forward-looking statements contained herein represent the Company&#8217;s views only as of the date of this Report and the Company does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this Report except as required by law. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7a9a790c_ca0a_427d_8646_fdd7e62f3db0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Signature</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October 19, 2023</p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20231018xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/19/2023 12:43:42 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">PTC Therapeutics Announces Evrysdi</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;"> Royalty Agreement </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">with Royalty Pharma for Up To $1.5 Billion</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0pt 36pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">- </i><i style="color:#212121;font-family:'Arial','Helvetica','sans-serif';font-style:italic;">PTC to receive $1B in upfront cash for approximately 67% of outstanding royalties, with option for additional $500M </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">- </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">- </i><i style="color:#212121;font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Financing proceeds will be used to retire Blackstone debt obligations </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">and fund planned operations </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">-</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">SOUTH PLAINFIELD, N.J., October 19, 2023</b><font style="font-family:'Arial','Helvetica','sans-serif';"> &#8211; PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced an agreement with Royalty Pharma plc. to monetize up to $1.5 billion of the Evrysdi royalty stream. Under the agreement, Royalty Pharma acquires additional royalties on Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date. PTC maintains all economics associated with up to $250 million in remaining commercial sales milestones associated with Evrysdi global net sales.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;"><a name="_Hlk45517696"></a></font><font style="font-family:'Arial','Helvetica','sans-serif';">This agreement builds on the previous strategic partnership established with Royalty Pharma in 2020. The initial agreement was for the monetization of approximately 43% of the Evrysdi royalty stream for $650 million. As a result of the current agreement, PTC will maintain ownership of approximately 19% of the Evrysdi royalty stream pending any exercise of future options by PTC or Royalty Pharma. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The proceeds from the financing will be used to retire all outstanding debt obligations with Blackstone Life Sciences and to fund planned operations.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;We are pleased to expand our existing strategic partnership with Royalty Pharma,&#8221; said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics. &#8220;This non-dilutive financing provides PTC with the capital to support operations and allows for increased operational and financial flexibility by removing the Blackstone debt obligation from our balance sheet. In addition, the deal structure provides important flexibility for additional non-dilutive capital over the next two years.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;We are excited to acquire an additional royalty interest in Evrysdi, a convenient, oral therapy that has transformed and benefited the lives of SMA patients worldwide,&#8221; said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. &#8220;This is our second transaction with PTC, which builds on our longstanding partnership, and highlights our ability to structure creative, win-win funding solutions for our partners.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Transaction Terms</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Following the transaction announced today, PTC has agreed to sell approximately 67% of both the outstanding 57% of the Evrysdi royalties and the outstanding royalty over the existing cap from the previous royalty financing agreement with Royalty Pharma.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Additionally, until December 31, 2025, PTC will have the option to sell the remainder of the Evrysdi royalty to Royalty Pharma for $500 million in five $100 million tranches, less royalties received. If fewer than three of these options are exercised, Royalty Pharma has the option to purchase 50% of the remaining PTC royalty for $250 million less royalties received until March 31, 2026.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Advisors</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-size:11pt;"><a name="_Hlk148470709"></a></font><font style="font-family:'Arial','Helvetica','sans-serif';">Wilmer Cutler Pickering Hale and Dorr LLP</font><font style="font-family:'Arial','Helvetica','sans-serif';"> acted as legal advisor to PTC Therapeutics on the transaction. </font><font style="font-family:'Arial','Helvetica','sans-serif';">Goodwin Procter, Fenwick &amp; West and Maiwald acted as legal advisors to Royalty Pharma.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About Evrysdi (risdiplam) </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to survival motor neuron (SMN) protein deficiency. Evrysdi is administered daily at home in liquid form and non-invasively by mouth or by feeding tube.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Evrysdi is designed to treat SMA by increasing and sustaining the production of SMN protein in the central nervous system (CNS) and peripheral tissues. SMN protein is found throughout the body and is critical for maintaining healthy motor neurons and core motor functions such as swallowing, speaking, and breathing. Evrysdi is currently approved in over 100 countries. The Evrysdi SMA program is a collaboration between PTC, the SMA Foundation, and Roche.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About PTC Therapeutics, Inc.</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC&#39;s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC&#39;s mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC&#39;s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, Instagram, LinkedIn and Twitter at @PTCBio. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;font-weight:bold;">For More Information:</b><b style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;font-weight:bold;"><br></b><font style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;font-weight:bold;">Investors:</b><b style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">Kylie O&#39;Keefe</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;background:#ffffff;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 300-0691</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;background:#ffffff;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">kokeefe@ptcbio.com </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;font-weight:bold;">Media:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Jeanine Clemente</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 912-9406</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">jclemente@ptcbio.com </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;font-weight:bold;">Forward Looking Statements:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historical fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC; advancement of PTC&#39;s joint collaboration program in SMA, including the commercialization of any products therein or royalty or milestone payments; PTC&#39;s strategy, future operations, future financial position, future revenues and, projected costs; PTC&#39;s expected use of proceeds from the agreement with Royalty Pharma including PTC&#8217;s intentions to pay off all obligations </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">under and retire all outstanding debt obligations with Blackstone Life Sciences; and the objectives of management. Other forward-looking statements may be identified by the words &quot;guidance&quot;, &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;continue,&quot; and similar expressions.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:16.5pt 0pt 16.5pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC&#39;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC&#39;s products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to the commercialization of Evrysdi under our SMA collaboration; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of Evrysdi or any of PTC&#39;s other products or product candidates; PTC&#39;s scientific approach and general development progress; and the factors discussed in the &quot;Risk Factors&quot; section of PTC&#39;s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC&#39;s other filings with the SEC. You are urged to carefully consider all such factors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:16.5pt 0pt 16.5pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product or product candidate will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Evrysdi.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:16.5pt 0pt 16.5pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The forward-looking statements contained herein represent PTC&#39;s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tmb-20231018.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/19/2023 12:43:49 AM-->
<!--Modified on: 10/19/2023 12:43:49 AM-->
<xsd:schema targetNamespace="http://www.ptcbio.com/20231018" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20231018" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20231018_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20231018_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>tmb-20231018_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/19/2023 12:43:49 AM-->
<!--Modified on: 10/19/2023 12:43:49 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>tmb-20231018_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/19/2023 12:43:49 AM-->
<!--Modified on: 10/19/2023 12:43:49 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20231018.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638332730298596154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638332730298596154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638332730298596154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638332730298596154" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638332730298596154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638332730298596154" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638332730298596154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638332730298596154" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638332730298606134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638332730298606134" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638332730298606134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638332730298606134" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638332730298606134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638332730298606134" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638332730298606134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638332730298606134" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638332730298606134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638332730298606134" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638332730298606134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638332730298606134" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638332730298606134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638332730298606134" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638332730298606134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638332730298606134" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638332730298606134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638332730298606134" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638332730298606134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638332730298606134" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638332730298616118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638332730298616118" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638332730298616118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638332730298616118" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638332730298616118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638332730298616118" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638332730298616118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638332730298616118" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638332730298616118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638332730298616118" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638332730298616118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638332730298616118" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638332730298616118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638332730298616118" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638332730298616118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638332730298616118" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140043411722384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 18, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 18,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>tmb-20231018x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmb-20231018.xsd" xlink:type="simple"/>
    <context id="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2023-10-18</startDate>
            <endDate>2023-10-18</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Tc_96dA-KGkLkmcqdKvZIIbVg_2_1">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Tc_vwTcQjKGxUanAV1kMfGZaQ_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Narr_EZoJRqzjuk2w0yOB76aKYw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Narr_wEVWRWI2kESkF5MiWlGf6Q">2023-10-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Narr_okMUaYASh0W7HY9LocRYrg">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Tc_ucEgepRznEqlUtNZhqNvIA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Tc_qLRBi6oEU0CAREPcFvL3Fw_1_2">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Tc_f7U3dMiFHkCtrj4ah5oikg_1_4">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Tc_gRSowEp3lkOb1W0sy0z4hA_1_0">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Narr_vqWhyyVuTkesEdhmYvJ5qw">South Plainfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Narr_wj9jbgWEJUypsU4QmeR4kA">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Tc_wXAR1LIHNkSUXKMLmP98Rw_2_2">07080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Narr_wxt7V5DOOUmphhNYfC7hlw">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Narr_wBOEK6X62k-6XBdnSHrS5A">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Narr_f9RtLTDHjk-7RF1EA4rpZg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Narr_tzzOEoQYSkWPEpJQsbG3Ng">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Narr_t5dTlvCuCEKAl17kaHJ1Ng">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Narr_PdndMp6y3UyYRgNvVS-HcA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Tc_13I3HE1VyUuj29pEBv_DlA_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Tc__NtkylRUVU2khUPonaiqow_2_2">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Tc_l3woA2JwCE61GH4m-NoWeA_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ"
      id="Narr_YAUnj_4JkkiFYDEpZ3Kq1A">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4$L! A0#%     @ ?$!35]#RK1SN    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ?$!35YE<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " !\0%-7%F7$W%8$  "Z$   &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ?$!35Y^@&_"Q @  X@P
M  T              ( !F0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !\
M0%-7EXJ[',     3 @  "P              @ %U#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " !\0%-7'#AEZC\!   \ @  #P              @ %>$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ?$!35R0>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ ?$!35V60>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tmb-20231018x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tmb-20231018.xsd</File>
    <File>tmb-20231018_lab.xml</File>
    <File>tmb-20231018_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="tmb-20231018x8k.htm">tmb-20231018x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tmb-20231018x8k.htm": {
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20231018",
   "dts": {
    "schema": {
     "local": [
      "tmb-20231018.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20231018_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20231018_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20231018x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20231018x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_18_2023_To_10_18_2023_EQ0GzKBuDE2OXMiuPz7QGQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20231018x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001070081-23-000056-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-23-000056-xbrl.zip
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M?!P">F"ETT1#+8.##B3"P OH0D>G6[+NMFJ05H+;TM5ECL?C<6C1VBDCW:(
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M6T_R@5:+#!O$5M-[*/.)W I[*/HW?>'OAZ&8M3C[9X0)\HR3H==:#VE%BT5
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M! +J;R)$!/ 9@@(%8(O%&LQI'$,")H@Q'(;@@>%@A0!P':MM.9;K =-,@SQ
M+CM1 I)H+<L]MHS2@)3T94?;[=DMI^4!M]5O>_UV#PPG1^A$4ESB"M@0D[_Z
MZF,AAP4R6\+[.XX'QEJ(N&_;V^W6VGH692L9P''M[Y.GF;]&$30QX0(2'QE
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M Q2EA<KRT*']!-3)]-+\\.W]T?45=1L?U>%I[^@K_=#5$=0>=0*V!.5>%LG
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MY^W+K<C=/88O(C^(J!N2T",=9J*,"8%4=>+Y1"WM6B_$ Z]'P@'#1I$/=BD
MW+HV!]3M,](P0P*OU9I>W-+HMR&?#NR0Y>&]R>ICG^6G/AW#%^C1();;;.SY
M(=F-?X/[X  U0L(F& ;T^6MFO:@3$L_J/O2J"-2\VK&OP[H%H(R@UX%%9S.
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ML2YB%=7\>](#T&&ML -8.$(&75NX(32P1Y$34I=Y4>#,2 ":+NC-^.?R \\
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MBJ,%?#!?#(;[SH@-6,!S#WT6XB8S&A*3^2'%(,!Z2"P.*N5G!KR+G!E1*YQ
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M(WJJ4MQ*WF-+WN6 R?HJS*S+<,7-69&</'@D%,G<8WX!!/G\IGURKZ<(/9'
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M^(E9"G0]/GRUH^UL)-1*0=$>>GHW+?M+F6'ADXOT\&^49&SI^#3/BWTNM#P
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M;6(M,C R,S$P,3@N>'-D4$L! A0#%     @ ?$!35PF;@Z]J!0  \SL  !0
M             ( !H@,  '1M8BTR,#(S,3 Q.%]L86(N>&UL4$L! A0#%
M  @ ?$!35WBV1[]S!   \R4  !0              ( !/@D  '1M8BTR,#(S
M,3 Q.%]P<F4N>&UL4$L! A0#%     @ ?$!35QO]YE/^(@  (.$  !,
M         ( !XPT  '1M8BTR,#(S,3 Q.'@X:RYH=&U02P$"% ,4    " !\
M0%-7+G[9*MT1  "E4P  %P              @ $2,0  =&UB+3(P,C,Q,#$X
A>&5X.3ED,2YH=&U02P4&      4 !0!( 0  )$,

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
